This workshop is jointly organized by Carsten Müller-Tidow and Andreas Trumpp and aims to strengthen the ties between fundamental research on the role of stem cells in normal and malignant tissues and research in oncology. The translational side of cancer stem cell research will be especially highlighted. The  workshop will take place on Sunday, September 16, opening the program of the SCC 2018 conference.

During this workshop, clinical experts with special experience in translational research will bridge the gap between laboratory based research and clinical trials. For this purpose, we focus on AML where several translational and early clinical trials to target Leukemic Stem Cells are underway. Speakers from Germany and abroad will present recent results for clinicians but also basic researchers to highlight burning questions in the field as well as current strategies to improve therapy outcome.

Confirmed Speakers:

  •  Gerhard Ehninger, University Hospital Carl Gustav Carus, Dresden University
    Topic: Novel immunotherapeutic approaches 
  • Catriona Jamieson, UC San Diego
    Topic: Detection and targeting of epitranscriptomic deregulation in leukemia stem cells
  • Jan Krönke, Ulm University Medical Center, Germnay
    Topic: Targeted protein degradation in hematologic malignancies
  • Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, USA
    Title: Sensitivity and resistance to novel anti-leukemic therapies
  • Daniel A. Pollyea, University of Colorado School of Medicine , Aurora, USA
    Topic: BCL-2 Inhibitors in AML therapy
  • Richard Schlenk, NCT Heidelberg, Germany
    Topic: Targeting FLT3 in AML
  • Hubert Serve, Universitätsklinikum Frankfurt Frankfurt, Germany
    Topic: Syk-Inhibition in the treatment of AML
  • Ulrich SteidlAlbert Einstein College of Medicine, New York, USA
    Topic:: Targeting the Origins of MDS and AML
  • Marion Subklewe, University Hospital Munich and Gene Center, LMU Munich
    Topic: Harnessing the T cell response in AML
Full Workshop Program

Workshop Supporters

We would like to thank our Sponsors for the Clinical Workshop on Innovative Strategies to Target AML:

Abbvie Deutschland GmbH & Co. KG

Amgen GmbH

Celgene GmbH

Hexal AG

Jazz Pharmaceuticals GmbH


MSD Sharp & Dohme GmbH

Novartis Pharma GmbH

Roche Pharma AG

Shire Deutschland GmbH